Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model
Abstract Recently, several types of systemic therapy using tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) have been performed for advanced renal cell carcinoma (aRCC) patients; however, the optimal strategy of sequential treatment with these agents has not been well establishe...
Main Authors: | Hiromitsu Watanabe, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Takayuki Sugiyama, Atsushi Otsuka, Hideaki Miyake |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-37857-9 |
Similar Items
-
Robot‐assisted radical nephrectomy and inferior vena cava tumor thrombectomy using the novel surgical robot platform, hinotori: Initial experience with two cases
by: Daisuke Motoyama, et al.
Published: (2024-03-01) -
Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01) -
Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01) -
Axitinib-induced posterior reversible encephalopathy syndrome in a patient with renal cell carcinoma
by: Euihyun Sung, et al.
Published: (2022-12-01) -
A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)